Zanidatamab clinical trials
Also written ZW25, ZIIHERA® and JZP598.
How each study uses zanidatamab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the zanidatamab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 20 Nov 2024 · ZIIHERA · BLA 761416 (FDA, Drugs@FDA)
- European Union
- 27 Jun 2025 · Ziihera · EMEA/H/C/006380 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
29 studies that test it; most in 2026 (9); 2 more planned to start later
| Year | Studies |
|---|---|
| 2010 | 1 |
| 2016 | 1 |
| 2019 | 2 |
| 2020 | 3 |
| 2021 | 3 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 4 |
| 2025 | 4 |
| 2026 | 9 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 11 · Other 20
Jazz Pharmaceuticals (10) · UNICANCER (3) · M.D. Anderson Cancer Center (2) · QuantumLeap Healthcare Collaborative (2) · BeOne Medicines (1) · Memorial Sloan Kettering Cancer Center (1) · Anhui Provincial Hospital (1) · Zhifeng Zhao, PhD (1)
Often tested with
Tested in the same studies.
Tislelizumab (4) · ALX148 (2) · Futibatinib (2) · Ivosidenib (2) · Trastuzumab (2) · Neratinib (2) · Niraparib (2) · Cisplatin (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 3, 1 in phase 3
Studies that test zanidatamab, phase 3 first.
- Jun 2027Personalized Medicine for Advanced Biliary Cancer PatientsPhase 3 · UNICANCER
- Dec 2026A Phase 2 Study of Zanidatamab in Patients With HER2-expressing TumorsPhase 2 · Jazz Pharmaceuticals
- Dec 2026Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Postive Advanced Gastroesophageal AdenocarcinomaPhase 2 · Canadian Cancer Trials Group
Studies
Open first, then newest update. How each study uses zanidatamab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 31
- A Phase 2 Study of Zanidatamab in Patients With HER2-expressing TumorsRecruitingPhase 2Jazz PharmaceuticalsNCT06695845Written as Zanidatamab
- A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast CancerRecruitingPhase 2Jazz PharmaceuticalsNCT07102381Written as Zanidatamab
- A Phase 1a/1b Of Zanidatamab In Combination With Zongertinib In HER2-Mutated Non-Small Cell Lung Cancer (NSCLC)Not yet recruitingPhase 1M.D. Anderson Cancer CenterNCT07899801Written as Zanidatamab
- Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract CancerRecruitingPhase 3Jazz PharmaceuticalsNCT06282575Written as Zanidatamab
- AACR Adaptive Biomarker-Driven Organ Preservation Trial in Gastroesophageal AdenocarcinomasRecruitingPhase 2American Association for Cancer ResearchNCT07290985Written as Zanidatamab
- Zanidatamab Combined With Liposomal Irinotecan and Capecitabine for Second-line Treatment of HER2-positive Unresectable Biliary Tract TumorsNot yet recruitingPhase 2Anhui Provincial HospitalNCT07841873Written as Zanidatamab
- PRE-ISPY Phase I/II Oncology Platform ProgramRecruitingPhase 1/2QuantumLeap Healthcare CollaborativeNCT05868226Written as Zanidatamab
- A Phase 2 Single-Arm Open-Label Pilot Trial Evaluating Zanidatamab (ZW25) in Patients With Early Stage HER2/Neu Positive (HER2+) Breast Cancer (BC)RecruitingPhase 2M.D. Anderson Cancer CenterNCT05035836Written as Zanidatamab
- Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Postive Advanced Gastroesophageal AdenocarcinomaRecruitingPhase 2Canadian Cancer Trials GroupNCT06043427Written as Zanidatamab
- Investigating Precision Medicine in the Adjuvant Setting in Biliary Tract CancerNot yet recruitingPhase 3UNICANCERNCT07745296Written as Zanidatamab + Capecitabine
- Zanidatamab Combined With Chemotherapy as Neoadjuvant/Conversion Therapy for HER2-Positive (IHC 3+ or IHC 2+) Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: a Phase II Open-Label StudyNot yet recruitingPhase 2Zhifeng Zhao, PhDNCT07685704Written as Zanidatamab
- Zanidatamab in Combination With Pembrolizumab and Chemotherapy in HER2 and PD-L1 Positive Metastatic Gastroesophageal Adenocarcinoma (GEA) PatientsRecruitingPhase 2Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestNCT07176312Written as Zanidatamab
- An Exploratory Study of Zanidatamab in HER2-positive Advanced Tumor After at Least One Line of Standard TherapyNot yet recruitingPhase 2Haihua YuanNCT07631871Written as Zanidatamab
- Personalized Medicine for Advanced Biliary Cancer PatientsRecruitingPhase 3UNICANCERNCT05615818Written as Zanidatamab
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerRecruitingPhase 2QuantumLeap Healthcare CollaborativeNCT01042379Written as Zanidatamab
- Zanidatamab Before Surgery for the Treatment of HER2 Positive Colon and Rectal Cancer in Patients Planned for Curative Intent TreatmentRecruitingPhase 2Emory UniversityNCT07405476Written as Zanidatamab
- Perioperative Zanidatamab and Chemotherapy for HER2 Positive Gastroesophageal CancerNot yet recruitingPhase 1/2Universitaire Ziekenhuizen KU LeuvenNCT07477444Written as Zanidatamab Combined with Chemotherapy
- A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast CancerRecruitingPhase 3Jazz PharmaceuticalsNCT06435429Written as Zanidatamab
- Neoadjuvant Zanidatamab + Tislelizumab + Chemotherapy for Selective Bladder Preservation in HER2-Positive MIBCRecruitingPhase 2Fujian Medical University Union HospitalNCT07296705Written as Zanidatamab
- Clinical Trial Evaluating the Activity of Zanidatamab for the Treatment of Patients With Solid Tumors With an Alteration of the HER2 Gene.RecruitingPhase 2UNICANCERNCT07192068Written as Zanidatamab
See all 31 studies that test zanidatamab →
Given beside what is tested · 3 — zanidatamab is usual care or a partner of the new treatment
- Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has SpreadRecruitingPhase 1/2Boehringer IngelheimNCT06324357Written as zanidatamab
- Phase Ib/II Study of Zanidatamab Plus Tucatinib and Chemotherapy in HER2-Positive Advanced Breast CancerNot yet recruitingPhase 1/2MedSIRNCT07494448Written as Zanidatamab
- Anti-HER2 Bispecific Antibody Zanidatamab (ZW25) Activity in Combination With Chemotherapy With/Without TislelizumabCompletedPhase 1/2BeiGeneNCT04276493Written as Zanidatamab
What changed recently
From the registry's own updates since Oct 18, 2026.
Results posted1
Newly registered1
Codes
What other systems call zanidatamab · ClinicalTrials.gg INT002015
- MeSH (NLM) C000726995zanidatamabConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) Z20OC92TDIZANIDATAMABConfirmed FDA, NLM
- NCI Thesaurus C130010ZanidatamabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000726995 | zanidatamab | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | Z20OC92TDI | ZANIDATAMAB | Confirmed FDA, NLM |
| NCI Thesaurus | C130010 | Zanidatamab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.